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Objective: Transforming growth factor-b (TGF-b) plays a critical role in cartilage homeostasis and
deregulation of its signalling is implicated in osteoarthritis (OA). TGF-b isoforms signal through a pair of
transmembrane serine/threonine kinases known as the type I and type II TGF-b receptors. Endoglin is
a TGF-b co-receptor that binds TGF-b with high afﬁnity in the presence of the type II TGF-b receptor. We
have previously shown that endoglin is expressed in human chondrocytes and that it forms a complex
with the TGF-b signalling receptors. However, the functional signiﬁcance of endoglin expression in
chondrocytes is unknown. Our objective was to determine whether endoglin regulates TGF-b/Smad
signalling and extracellular matrix (ECM) production in human chondrocytes and whether its expression
varies with chondrocyte differentiation state.
Method: Endoglin function was determined by overexpression or antisense morpholino/siRNA knock-
down of endoglin in human chondrocytes and measuring TGF-b-induced Smad phosphorylation, tran-
scriptional activity and ECM production. Alterations in endoglin expression levels were determined
during subculture-induced dedifferentiation of human chondrocytes and in normal vs OA cartilage
samples.
Results: Endoglin enhances TGF-b1-induced Smad1/5 phosphorylation and inhibits TGF-b1-induced
Smad2 phosphorylation, Smad3-driven transcriptional activity and ECM production in human
chondrocytes. In addition, the enhancing effect of endoglin siRNA knockdown on TGF-b1-induced
Smad3-driven transcription is reversed by ALK1 overexpression. Furthermore, endoglin levels are
increased in chondrocytes following subculture-induced dedifferentiation and in OA cartilage as
compared to normal cartilage.
Conclusion: Together, our results suggest that endoglin regulates the balance between TGF-b/ALK1/
Smad1/5 and ALK5/Smad2/3 signalling and ECM production in human chondrocytes and that endoglin
may represent a marker for chondrocyte phenotype.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Transforming growth factor-b (TGF-b) is a multifunctional
regulator of cartilage repair and homeostasis with critical roles in
chondrocyte proliferation, differentiation and extracellular matrix
(ECM) production1e3. Studies inmice have shown that disruption ofnie Philip, Division of Plastic
ue, Room C9-158, Montreal,
x: 1-514-934-8289.
s Research Society International. PTGF-b signalling leads to the development of degenerative joint
disease resembling human osteoarthritis (OA)4,5. Furthermore,
TGF-b receptor expression and TGF-b signalling are markedly
reduced in murine models of OA6. Conversely, TGF-b treatment has
been reported to result in OA-like lesions in rat knee joints sug-
gesting that excessive TGF-b action may also play a role in OA
pathogenesis7,8. Thus, factors that increase or decrease TGF-
b activity may be important in maintaining chondrocyte phenotype
and preventing cartilage diseases such as OA.
TGF-b isoforms (b1, b2, b3) signal through a pair of trans-
membrane serine/threonine kinases known as the type I (TbRI or
activin receptor-like kinase-5; ALK5) and the type II (TbRII)ublished by Elsevier Ltd. All rights reserved.
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in the formation of a heteromeric receptor complex10,11. TbRII is
a constitutively active kinase and phosphorylates ALK5 within the
TGF-b receptor complex leading to activation of ALK5 kinase
activity. The activated ALK5 propagates the TGF-b signal by phos-
phorylating intracellular Smad2 and Smad3. Besides signalling
through the ALK5/Smad2/3 pathway, TGF-b has also been shown to
signal through another type I TGF-b receptor named ALK1 leading
to phosphorylation of Smad1 and Smad512,13. Phosphorylated
Smad2/3 and phosphorylated Smad1/5 associate with Smad4 and
translocate to the nucleus where they interact with various tran-
scriptional coactivators, corepressors and transcription factors to
modulate target gene expression14.
Endoglin is a TGF-b co-receptor that has been shown to
modulate TGF-b signalling in endothelial cells15,16. Endoglin binds
TGF-b1 and -b3 with high afﬁnity in the presence of TbRII but does
not bind TGF-b215,16. Although endoglin is not a signalling receptor,
it has been shown to associate with the TGF-b signalling receptors
(TbRII, ALK1 and ALK5) and to modulate their phosphorylation
status as well as downstream Smad-dependent and Smad-inde-
pendent signalling in endothelial cells17. We have previously shown
that endoglin is expressed in human chondrocytes and that it forms
a heteromeric complex with TbRII and TbRI (ALK1 and ALK5)18.
However, the functional signiﬁcance of endoglin expression in
chondrocytes is unknown. Here we show that endoglin enhances
TGF-b1-induced Smad1/5 phosphorylation but inhibits TGF-b1-
induced Smad2 phosphorylation, Smad3-driven transcriptional
activity and ECM protein (type II collagen and PAI-1) expression in
human chondrocytes.We also demonstrate that the enhanced TGF-
b-induced Smad3-driven transcription by endoglin siRNA knock-
down is reversed by ALK1 overexpression. Furthermore, we show
that endoglin expression is increased in human chondrocytes
following subculture-induced dedifferentiation in vitro and in OA
cartilage as compared to normal cartilage in vivo. Taken together,
our results establish endoglin as a regulator of TGF-b/Smad sig-
nalling and ECM production in human chondrocytes and suggest
that endoglin may represent a potential marker for chondrocyte
dedifferentiation and/or phenotype.
Method
Cell culture
The SV40-immortalized human chondrocyte cell lines, C28/I2
and tsT/AC62, have been described previously19. The C28/I2 cell line
was developed from chondrocytes isolated from juvenile human
costal cartilage and immortalized by retroviral infection of the SV40
large T antigen20. The tsT/AC62 cells were developed from chon-
drocytes isolated from adult human articular cartilage and
immortalized by retroviral infection of a temperature-sensitive
mutant of SV40 large T antigen that is functional at 32C but not at
37C19. Primary chondrocytes were isolated from human osteoar-
thritic articular cartilage obtained intraoperatively from adult
arthroplasty specimens or from normal adult cartilage obtained
from traumatic open joint injuries with no evidence of degenerate
joint disease (normal cartilage, N). All procedures were approved
by the Research Ethics Board of the McGill University Health Center
and all cartilage sampleswere obtainedwith informed consent. The
cartilage was rinsed with cold phosphate buffered saline (PBS),
minced and then incubated for 1 h at 37C with 1 mg/ml Pronase
followed by overnight digestion at 37C with 1 mg/ml collagenase.
The suspension was passed through a 70 mm cell sieve and chon-
drocytes were collected by 5 min centrifugation, washed with PBS
and plated at a density of 2.5105 cells/cm2. Alternatively, chon-
drocyte cultures were established by outgrowth of explants asdescribed previously21. All cells were cultured in DMEM/F12 con-
taining 10% fetal bovine serum and antibiotics and maintained at
37C in a humidiﬁed incubator under 5% CO2/air (Supplementary
information for details).
The 3-dimensional (3-D) alginate culture system for chon-
drocyte redifferentiation has been described previously19,20. Brieﬂy,
chondrocytes (4106 cells/ml) were suspended in a 1.2% alginate
solution and passed drop-wise through a 25-gauge needle into
a 102 mM CaCl2 solution resulting in the formation of alginate
beads. The beads were washed with 0.15 M NaCl and transferred to
culture ﬂasks with serum-containing media. The alginate beads
were cultured for 21 days and the media changed every third day.
Alginate beads were depolymerised with 55 mM sodium citrate/
0.15 M NaCl and the recovered chondrocytes washed in PBS,
resuspended in serum-containing media, plated (2.5105 cells/
cm2) and grown to conﬂuence. Subculture-induced dedifferentia-
tionwas performed by serially passaging conﬂuent chondrocytes at
a 1:2 split ratio for up to 12 passages. Cells at passage 1e2 are
designated as ‘early passage’ and cells at passage 10e12 are
designated as ‘late passage’. Chondrocyte morphology was visual-
ized by phase contrast microscopy and images were captured with
a digital camera.
Afﬁnity labelling
Afﬁnity labelling was performed as described previously13.
Brieﬂy, chondrocytes were washed with cold binding buffer
(Supplementary information for details) and incubated for 3 h at
4C with 100 pM of [125I]TGF-b1. [125I]TGF-b1-labelled complexes
were covalently cross-linked with 1 mM bis-sulfosuccinimidyl
suberate. Membrane extracts were prepared in solubilisation buffer
(Supplementary information for details). Protein concentrations
were determined using a Protein Assay Kit. Samples were resolved
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), the gels stained with Coomassie blue and radioactive bands
were visualized by autoradiography.
Transfections
Endoglin overexpression: Chondrocytes were transiently trans-
fected with endoglin or its empty vector (EV) using Lipofectamine
2000 according to the manufacturers’ instructions. Endoglin
knockdown: Chondrocytes were transfected with endoglin-speciﬁc
antisense morpholinos or control morpholinos using i-PEI trans-
fection reagent according to the manufacturers’ instructions.
Alternatively, chondrocytes were transfected with endoglin-
speciﬁc siRNA, ALK1-speciﬁc siRNA or control siRNA as described
previously22.
Western blot analysis
Chondrocytes transfected with (1) endoglin or EV, (2) endoglin-
speciﬁc or control morpholinos or (3) endoglin-speciﬁc siRNA,
ALK1-speciﬁc siRNA or control siRNA were grown overnight in
serum-containing media. Chondrocytes were washed with PBS,
serum-starved for 3 h and then treated for 45 min or 24 h with
0e100 pM TGF-b1. Cell lysates were prepared in RIPA buffer
(Supplementary information for details). Samples were resolved by
SDS-PAGE and transferred to nitrocellulose membranes.
Membranes were blocked with Trisebuffered salineeTween 20
(Supplementary information for details) and incubated overnight
at 4C with the indicated primary antibodies (Supplementary Table
1 for antibody information). Membranes were washed with TBST
and incubated with a horseradish peroxidase (HRP)-conjugated
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chemiluminescence (ECL) system.
Luciferase assays
C28/I2 cells were transfected with (1) Eg or EV plasmids or (2)
endoglin-speciﬁc siRNA or control siRNA. In some experiments,
endoglin-speciﬁc siRNA and control siRNA transfected cells
were co-transfected with wild-type (WT) ALK1, constitutively
active ALK1 (QD) or EV. Cells were co-transfected with Smad3-
responsive CAGA12-lux23 or Smad2/3-responsive 3TP-lux24
luciferase reporter constructs. All cells were co-transfected with
pCMV-b-galactosidase. Cells were then treated for 24 h with
0e100 pM of TGF-b1 or TGF-b2 under serum-free conditions. Cell
lysates were prepared and analyzed for luciferase and b-galactosi-
dase activity as described previously13. The data are presented as
a fold-change in luciferase activity from control (absence of ligand
addition and/or transfection with control siRNA/EV alone).
Statistical analysis
Means calculated from replicates of three or more independent
experiments were used for statistical analysis. Differences between
the means were compared using Analysis of Variance (ANOVA)
followed by post hoc pair-wise comparision using Bonferroni t-test
(Systat 11.0; Systat, Chicago, IL).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from chondrocytes and reverse tran-
scribed using (MMLV)-RT and oligo-dT primer. PCR was performedFig. 1. Endoglin inhibits TGF-b1-induced Smad2 phosphorylation in human chondrocytes. (
morpholino oligonucleotides or control (C) morpholino oligonucleotides were incubated for
prepared and analyzed by Western blot using anti-phosphoSmad2 or anti-STAT3 antibodies
(Eg) or control (C) morpholinos were afﬁnity labelled with [125I]TGF-b1. Cell lysates were
Coomassie blue staining conﬁrms that equal amounts of protein were loaded in each lane. (C
or control (C) siRNA were treated for 30 min with 0e50 pM TGF-b1 under serum-free cond
Smad2, anti-Smad2, anti-endoglin or anti-STAT3 antibodies as indicated. For A and B, the
representative of three independent experiments. Eg ¼ endoglin; BG ¼ betaglycan.using human endoglin25 and human GAPDH primers26 and Taq
polymerase (Supplementary information for details). PCR products
were resolved by agarose gel electrophoresis and visualized by
ethidium bromide staining13.
Cartilage extraction
Total protein was extracted from human articular cartilage as
described previously27. Brieﬂy, cartilage tissue was pulverized
under liquid nitrogen using a biopulverizer (Biospec Products Inc.,
Bartlesville, OK) and then homogenized in GuCl extraction buffer
[4 M GuCl/50 mM Tris, pH 7.5 and 1 mM ethylenediaminetetra-
acetic acid (EDTA)]. Samples were vortexed at 4C for 30 min,
centrifuged at 15,000g for 10 min at 4C and the supernatants
were collected and precipitated with 5 vol 100% ethanol at 20C.
Pellets were washed with 75% ethanol, dried, and resuspended in
8 M urea. Samples containing equivalent amounts of protein were
analyzed by Western blot using an anti-endoglin antibody.
Membranes were stained with Ponceau to conﬁrm equal protein
loading.
Immunohistochemistry
Cartilage tissue was ﬁxed in a periodate-lysine-para-
formaldehyde solution28 and embedded in a solution containing
two parts 20% sucrose phosphate buffer to one part O.C.T. embed-
dingmedium (Tissu-Tek, Miles, USA). Cryostat sections (8 mm)were
obtained, ﬁxed in 4% paraformaldehyde, washed in PBS and treated
with chondroitinase ABC for 1 h at 37C. The sections were washed
in PBS, blocked for 1 h at room temperature with 5% normal goat
serum and then incubated overnight at 4C with anti-endoglinA) Primary human articular chondrocytes treated with endoglin-speciﬁc (Eg) antisense
15 min with or without 100 pM TGF-b1 under serum-free conditions. Cell lysates were
as indicated. (B) Primary human articular chondrocytes treated with endoglin-speciﬁc
prepared and analyzed under non-reducing conditions by SDS-PAGE/autoradiography.
) Primary human articular chondrocytes transfected with endoglin-speciﬁc (Eg) siRNA
itions. Cell lysates were prepared and analyzed by Western blot using anti-phospho-
lanes were selected from non-adjacent regions of the same gel. Results shown are
Fig. 2. Endoglin enhances TGF-b1/ALK1-induced Smad1/5 phosphorylation in human
chondrocytes. (A) Primary human articular chondrocytes transfected with ALK1-
speciﬁc (ALK1) siRNA or control (C) siRNA were treated for 30 min without or with
50 pM TGF-b1 under serum-free conditions. (B) Primary human articular chondrocytes
transfected with endoglin-speciﬁc (Eg) siRNA or control (C) siRNA were treated for
30 min with 0e50 pM TGF-b1 under serum-free conditions. Cell lysates were prepared
and analyzed by Western blot using anti-phosphoSmad1/5, anti-Smad1, anti-endoglin
or anti-STAT3 antibodies. Results shown are representative of three independently
performed experiments.
Table I
Endoglin siRNA knockdown enhances TGF-b1-induced Smad3-driven (CAGA12-lux*)
transcriptional activity in human chondrocytes (C28/I2 cells)
siRNA TGF-b1 Fold-change 95% CI
Control  1.0 0 0
Control þ 100 15.8y 39.2
Endoglin  1.7 0.21 1.1
Endoglin þ 276.2 28.6y 70.9
* CAGA12-lux is a TGF-b responsive luciferase reporter gene.
y Signiﬁcantly different from each other; P¼ 0.006.
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and incubated at room temperature for 30 min with a HRP-conju-
gated anti-mouse secondary antibody. Immune complexes were
detected using the Vectastain ABC kit according to the manufac-
turers’ instructions (Vector Laboratories, Burlington, ON).
Results
Endoglin inhibits TGF-b1-induced Smad2 phosphorylation and
enhances TGF-b1-induced Smad1/5 phosphorylation in human
chondrocytes
The ability of endoglin to regulate TGF-b/Smad signalling in
human chondrocytes was examined by blocking endoglin expres-
sion in primary human articular chondrocytes using antisense
morpholinos and measuring TGF-b1-induced Smad2 phosphory-
lation. Fig. 1(A) demonstrates that blocking endoglin expression is
associated with enhanced TGF-b1-induced Smad2 phosphorylation
[Fig. 1(A) top panel]. Reprobing the membrane with an anti-STAT3
antibody conﬁrms that equivalent amounts of protein were loaded
in each lane [Fig 1(A), bottom panel]. Fig. 1(B) demonstrates that
cells transfected with Eg-speciﬁc antisense morpholinos display
markedly reduced levels of [125I]TGF-b1-bound (cell surface)
endoglin as compared to cells transfected with control morpholi-
nos. Western blot analysis also demonstrated that chondrocytes
transfected with endoglin-speciﬁc morpholinos display a marked
reduction in endoglin protein levels as compared to control mor-
pholino transfected cells (data not shown).
The effect of blocking endoglin expression on TGF-b1-induced
Smad2 phosphorylation was also examined using a siRNA-based
approach. Fig. 1(C) (top panel) shows that primary articular chon-
drocytes transfected with endoglin-speciﬁc siRNA display
enhanced TGF-b1-induced Smad2 phosphorylation as compared to
control morpholino transfected cells, particularly at lower doses
(i.e.,10 pM) of TGF-b1, without altering total Smad2 protein levels
[Fig. 1(C), second panel]. Fig. 1(C) (third panel) shows that endoglin
siRNA treated cells display markedly reduced levels of endoglin as
compared to control siRNA transfected cells. Reprobing the
membrane with an anti-STAT3 antibody conﬁrms that equal
amounts of protein were loaded in each lane [Fig. 1(C), bottom
panel].
We next examined whether endoglin regulates TGF-b/ALK1-
mediated phosphorylation of Smad1/5 in primary human articular
chondrocytes. Fig. 2(A) (top panel) shows that ALK1-speciﬁc siRNA
transfected primary chondrocytes display a marked reduction in
TGF-b1-induced Smad1/5 phosphorylation, without altering total
Smad1 levels [Fig. 2(A), bottom panel], conﬁrming the importance
of ALK1 in mediating TGF-b-induced Smad1/5 phosphorylation in
human chondrocytes13. Importantly, Fig. 2(B) demonstrates that
endoglin siRNA transfected chondrocytes display a marked reduc-
tion in TGF-b1-induced Smad1/5 phosphorylation as compared to
control cells [Fig. 2(B), top panel] without altering total Smad1
levels [Fig. 2(B), second panel]. The relative levels of endoglin and
STAT3 (loading control) in endoglin-speciﬁc siRNA and control
siRNA transfected cells are indicated [Fig. 2(B), panels 3 and 4,
respectively].
Endoglin inhibits TGF-b1-induced Smad3-driven transcriptional
activity in human chondrocytes
The effect of endoglin on Smad3-driven signalling was
examined using the Smad3-responsive CAGA12-lux and Smad2/
3-responsive 3TP-lux luciferase reporter constructs in C28/I2
cells. Results shown in Table I demonstrate that endoglin siRNA
transfection leads to a signiﬁcant increase (P¼ 0.006) inTGF-b1-induced CAGA12-lux activity as compared to control
siRNA transfection. Similarly, endoglin siRNA treatment results
in increased TGF-b1-induced 3TP-lux activity (Supplementary
Fig. 1). Interestingly, endoglin siRNA transfection also leads to
enhanced TGF-b2-induced CAGA12-lux activity in these
cells (Supplementary Fig. 2), suggesting that endoglin regulates
TGF-b signalling in a TGF-b isoform-independent manner in
human chondrocytes. We also found that overexpression of
endoglin inhibited TGF-b1-induced CAGA12-lux activity
(Supplementary Fig. 3), supporting the results obtained with
siRNA.
We next examined whether the stimulatory effect of endo-
glin siRNA knockdown on TGF-b1-induced Smad3-driven tran-
scriptional activity could be reversed by ALK1 overexpression.
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enhanced TGF-b1-induced CAGA12-lux activity, as expected.
Importantly, co-transfection of WT or constitutively active (QD)
ALK1 leads to a signiﬁcant reduction in the stimulatory effect of
endoglin siRNA knockdown on TGF-b1-induced CAGA12-lux
activity [Fig 3(A), P¼ 0.006 and 0.002, respectively]. Expression
levels of endoglin and ALK1 proteins are depicted in Fig. 3(B)
and (C), respectively.
Endoglin inhibits TGF-b1-induced ECM production in human
chondrocytes
Our previous results have shown that TGF-b1 stimulates type II
collagen and PAI-1 protein production in human chondrocytes13.
The role of endoglin in regulating ECM production was ﬁrst
examined in primary human articular chondrocytes. Fig. 4(A)
demonstrates that endoglin siRNA transfected chondrocytes
display an increase in TGF-b1-induced type II collagen (top panel)
and an increase in (non-glycosylated) PAI-1 protein expression as
compared to control cells [Fig. 4(A), second panel]. PAI-1 is detected
as a double band andmay represent non-glycosylated (lower band)
and glycosylated (upper band) forms of PAI-1 which have been
reported previously29. Equal protein loading is veriﬁed by reprob-
ing the membrane with an anti-actin antibody [Fig. 4(A), third
panel]. The role of endoglin in regulating ECM production was also
examined in C28/I2 cells. Fig. 4(B) illustrates that endoglin siRNA
knockdown increases TGF-b1-induced type II collagen protein
production as compared to control siRNA transfected cells [Fig. 4
(B), top panel]. Endoglin siRNA transfected C28/I2 cells also
display a marked increase in TGF-b1-induced PAI-1 protein (atFig. 3. ALK1 overexpression reverses the effect of endoglin siRNA knockdown on TGF-b1-i
were transfected with endoglin-speciﬁc (Eg) siRNA or control (C) siRNA and WT or constitut
and CMV-b-galactosidase. Cells were treated for 24 h without or with 100 pM TGF-b1 und
galactosidase activities. Luciferase activity was normalized to b-galactosidase activity and
luciferase activity relative to the control (EV and control siRNA transfected cells not treated
endoglin-speciﬁc siRNA or control siRNA were analyzed by Western blot using an anti-end
loading. (C) Cell lysates from C28/I2 cells transfected with ALK1-WT, ALK1-QD or EV were an
an anti-actin antibody to conﬁrm equal protein loading. The results shown are representata dose of 100 pM TGF-b1) as compared to the control siRNA
transfected cells [Fig. 4(B), second panel].Endoglin expression is increased following subculture-induced
dedifferentiation
The effects of subculture-induced dedifferentiation on endoglin
expression were examined in early and late passage primary
human articular chondrocytes. Fig. 5(A) (top panel) shows that
endoglin protein levels are higher in late passage as compared to
early passage chondrocytes. Type II collagen protein levels are
lower in late passage as compared to early passage chondrocytes
[Fig. 5(A), middle panel] consistent with the process of chondrocyte
dedifferentiation30,31. Reprobing the membrane with an anti-STAT3
antibody conﬁrms that equal amounts of protein are loaded in each
lane [Fig. 5(A), bottom panel].
Endoglin expression in early and late passage primary articular
chondrocytes was also examined at the mRNA level. RT-PCR analysis
performed on total RNA extracted from early and late passage
chondrocytes indicates that endoglin mRNA levels are higher in late
passage as compared to early passage chondrocytes [Fig. 5(B), top
panel]. RT-PCR for GAPDH was performed as a control [Fig. 5(B),
second panel].Western blot analysis of cell lysates prepared from the
same cells conﬁrms that endoglin protein levels are higher in late
passage as compared to early passage chondrocytes [Fig. 5(B), third
panel]. Reprobing the membrane with an anti-STAT3 antibody
conﬁrms that equal amounts of protein are loaded in each lane [Fig. 5
(B), bottompanel]. Subculture-induced changes inmorphologyof the
human articular chondrocytes are shown [Fig 5(C)].nduced Smad3-driven transcriptional activity in human chondrocytes. (A) C28/I2 cells
ively active (QD) ALK1 or corresponding EV with CAGA12-lux (luciferase reporter gene)
er serum-free conditions. Cell lysates were prepared and assayed for luciferase and b-
data are presented as fold-increase [mean 95% conﬁdence interval (CI), N¼ 3] in
with TGF-b1; P-values are indicated). (B) Cell lysates from C28/I2 cells transfected with
oglin. The membrane was reprobed with anti-STAT3 antibody to verify equal protein
alyzed by Western blot using an anti-ALK1 antibody. The membrane was reprobed with
ive of three independent experiments.
Fig. 4. Endoglin inhibits TGF-b1-induced type II collagen and PAI-1 protein expression in human chondrocytes. (A) primary human articular chondrocytes or (B) C28/I2 cells were
transfected with endoglin-speciﬁc (Eg) or control (C) siRNA. The cells were treated for 24 h with 0e100 pM TGF-b1 under serum-free conditions. Cell lysates were prepared and
analyzed by Western blot using anti-type II collagen, anti-PAI-1, anti-endoglin and anti-actin antibodies. Results shown in A and B are each representative of two independent
experiments. Results shown are representative of four (A) and two (B) independent experiments, respectively.
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tsT/AC62 cells. Western blot analysis indicates that total endoglin
protein levels are higher in late passage as compared to early
passage tsT/AC62 cells [Fig. 6(A), top panel]. The type II collagen
protein levels are lower and the type I collagen (third panel) are
higher in late passage as compared to early passage tsT/AC62 cells
[Fig. 6(A), second and third panel, respectively], consistent with the
process of chondrocyte dedifferentiation30,31. Reprobing the
membrane with an anti-actin antibody conﬁrms that equal
amounts of protein are loaded in each lane. Cell surface endoglinFig. 5. Endoglin expression is increased in primary human articular chondrocytes followi
primary human articular chondrocytes were analyzed by Western blot using anti-endoglin (t
with an anti-STAT3 antibody (bottom panel) to conﬁrm that equal amounts of protein we
late passage primary human articular chondrocytes. Total RNA was analyzed by RT-PCR usi
PCR product sizes for endoglin (e.g., 411 bp) and GAPDH (226 bp) are indicated. Cell lysates w
panel) antibodies. (C) Cell morphology: Phase contrast microscopy of early and late passa
representative of three independent experiments.levels were also examined in early (E) and late (L) passage tsT/AC62
by afﬁnity labelling with [125I]TGF-b1. Fig. 6(B) shows that late
passage tsT/AC62 cells display higher levels of [125I]TGF-b1-asso-
ciated endoglin as compared to early passage cells. The morphol-
ogies of early and late passage tsT/AC62 cells are shown in Fig. 6(C).
Immediately (24 h) following transfer from alginate to monolayer
cultures, polygonal-shaped cells are observed [Fig 6(C), early
passage]. However, the cells progressively acquire amore elongated
‘ﬁbroblastic’ morphology following several passages in monolayer
[Fig 6(C), late passage].ng subculture-induced dedifferentiation. (A) Cell lysates from early and late passage
op panel) or anti-type II collagen (middle panel) antibodies. Membranes were reprobed
re loaded in each lane. (B) Total RNA and cell lysates were prepared from early and
ng endoglin- (top panel) and GAPDH-speciﬁc (second panel) oligonucleotide primers.
ere analyzed byWestern blot using anti-endoglin (third panel) and anti-STAT3 (bottom
ge primary human articular chondrocytes in monolayer culture. Results shown are
Fig. 6. Endoglin expression is increased in tsT/AC62 cells following subculture-induced dedifferentiation. (A) Cell lysates from early and late passage tsT/AC62 cells were analyzed
by Western blot using anti-endoglin (top panel), anti-type II collagen (second panel) or anti-type I collagen (third panel) antibodies. Membranes were reprobed with an anti-actin
antibody (bottom panel) to conﬁrm that equal amounts of protein were loaded in each lane. (B) Early and late passage tsT/AC62 cells were afﬁnity labelled with 100 pM of [125I]TGF-
b1. Membrane extracts were prepared, electrophoretically separated by 3e11% gradient SDS-PAGE under non-reducing conditions and levels of [125I]TGF-b1-associated endoglin
visualized by autoradiography. The lanes were selected from non-adjacent regions of the same gel. Coomassie blue staining conﬁrms that equal amounts of protein were loaded in
each lane. (C) Cell morphology: Phase contrast microscopy of early and late passage tsT/AC62 cells in monolayer culture. Results shown are representative of three independent
experiments.
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We next examined endoglin protein expression in vivo in cartilage
samples obtained from the knee of OA patients and normal controls.
Cartilage protein was extracted as described in the Method section
and analyzed by Western blot using an anti-endoglin antibody.
Results shown in Fig. 7(A) demonstrate that endoglin protein levels
are higher in OA as compared to normal cartilage. Ponceau staining of
themembrane conﬁrms that equal amounts of proteinwere loaded in
each lane. Similar results were obtained when comparing endoglin
protein levels in three different pairs of OA and normal cartilage
samples (data not shown). Endoglin expressionwas also examined in
human OA and normal cartilage by immunohistochemistry using an
anti-endoglin (SN6h, Dako) antibody. Fig. 7(B) demonstrates that OA
cartilage displays enhanced staining for endoglin as compared to
normal cartilage. No staining was detected when the primary anti-
body was omitted in parallel experiments (data not shown).
Discussion
TGF-b is a pleiotropic cytokine that plays a critical role in main-
taining cartilage homeostasis6,32. Although deregulation of TGF-bsignalling has been implicated in cartilage diseases such as OA6,32, the
factors that regulate TGF-b signalling in normal or diseased human
chondrocytes are unclear. We have previously shown that human
chondrocytes express several different TGF-b receptors including two
isoforms of TbRII (RII and RIIB), two different TbRIs (ALK5 and ALK1)
and the TGF-b co-receptors endoglin and betaglycan13,18,33. We have
shown that endoglin forms a heteromeric complex with TbRII and
TbRI (ALK5 and ALK1) in human chondrocytes13,18 as has been
demonstrated for endoglin in endothelial cells11,34e37. However, the
functional signiﬁcance of endoglin expression in human chon-
drocytes has not been examined. Here we show that endoglin
enhances TGF-b1-induced Smad1/5 phosphorylation but inhibits
TGF-b1-induced Smad2 phosphorylation, Smad3-driven (CAGA12-lux
and 3TP-lux) transcriptional activity and type II collagen and PAI-1
protein expression in human chondrocytes. Moreover, we present
evidence that endoglin expression is increased in human chon-
drocytes following subculture-induced dedifferentiation in vitro and
that endoglin expression levels are increased in human OA cartilage
as compared to normal cartilage in vivo. Collectively, our results
establish endoglin as a regulator of TGF-b signalling and ECM protein
production with opposing effects on the ALK1/Smad1/5 and ALK5/
Smad2/3 pathways in human chondrocytes and suggest that endoglin
Fig. 7. Endoglin expression is increased in OA cartilage as compared to normal carti-
lage. (A)Western blot: Protein was extracted from OA and normal cartilage as described
in Methods section. Samples were analyzed by Western blot using an anti-endoglin
antibody (top panel). The membrane was stained with Ponceau S to conﬁrm that equal
amounts of protein were loaded in each lane (bottom panel). The lanes were selected
from non-adjacent regions of the same gel. Results shown are representative of three
independent experiments performed on cartilage of three different OA and three
different normal donors. (B) Immunohistochemistry: Cryostat sections of OA and
normal cartilage were analyzed by immunohistochemistry using an anti-endoglin
(Dako, SN6h, 1:100 dilution) antibody. Detection was performed using Vectostain ABC
immunostaining kit. Results shown are representative of two independently per-
formed experiments.
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or the loss of chondrogenic phenotype.
Endoglin is a TGF-b co-receptor that has been shown to regulate
TGF-b signalling in endothelial cells12,17,38. Our present results
show that endoglin enhances TGF-b1-induced Smad1/5 phos-
phorylation but decreases TGF-b1-mediated Smad2 phosphoryla-
tion in human chondrocytes. In comparison, other studies report
conﬂicting data on the role of endoglin in regulating TGF-b-medi-
ated Smad1/5 and Smad2 signalling in different cell types. For
example, ectopic expression of endoglin in rat myoﬁbroblasts was
reported to increase phosphorylation (and total levels) of Smad239
whereas another study using ectopic expression of endoglin in rat
myoﬁbroblasts reported no signiﬁcant effect on TGF-b-induced
phosphorylation of Smad1 or Smad240. Conversely, studies using
endoglin-null mouse embryonic endothelial cells reported that
endoglin promotes TGF-b-mediated Smad1/5 signalling36,41
whereas another study using endoglin siRNA knockdown in
human bone marrow stromal cells reported that endoglin acts as
a positive regulator of both ALK1-induced Smad1 activation and
ALK5-induced Smad2 activation42. Taken together, these studies
suggest that endoglin differentially regulates TGF-b signalling via
ALK1/Smad1/5 and ALK5/Smad2 depending on cell-type and
cellular context. Our results suggest that endoglin differentially
regulates TGF-b/Smad signalling in human chondrocytes by
promoting TGF-b signalling through the ALK1/Smad1/5 pathway
and decreasing signalling through the ALK5/Smad2/3 pathway.Our previous work has demonstrated that ALK1 inhibits
TGF-b/ALK5-dependent Smad3-driven transcriptional activity
and ECM production in human chondrocytes13. Our present
results indicate that endoglin also inhibits TGF-b1/ALK5-induced
Smad3-driven transcriptional activity and ECM production in
human chondrocytes. Because we have shown that endoglin
interacts with ALK1 in human chondrocytes13 and that others
have shown endoglin to interact with, and promote signalling
through, ALK1 in endothelial cells to inhibit ALK5 signalling36, it
is plausible that endoglin regulates TGF-b/ALK5 signalling
through a similar mechanism in human chondrocytes. Our
results showing that endoglin promotes TGF-b1/ALK1 signalling
(i.e., Smad1/5 phosphorylation) and that overexpression of ALK1
can reverse the stimulatory effect of endoglin siRNA knockdown
on TGF-b1-induced CAGA12-lux activity are consistent with this
notion. Whether endoglin inhibits TGF-b/ALK5/Smad2/3 signal-
ling by promoting the TGF-b/ALK1/Smad1/5 pathway or by
regulating other pathways remains to be determined. Impor-
tantly, our ﬁnding that endoglin inhibits TGF-b-induced Smad3-
driven transcription provides further evidence for endoglin’s role
in inhibiting TGF-b-mediated ALK5/Smad2/3 signalling in human
chondrocytes.
Primary human articular chondrocytes maintain a rounded,
polygonal morphology in monolayer culture but undergo
a progressive change to an elongated ﬁbroblast-like morphology
over time, particularly after subculture43. Accompanying these
morphological changes is the loss of the chondrogenic (differenti-
ated) phenotype or ‘chondrocyte dedifferentiation’ which is char-
acterized by a decrease in type II collagen expression43. Our results
demonstrate that primary human articular chondrocytes and tsT/
AC62 cells display such changes in morphology and reduction in
type II collagen expression following serial passage in monolayer
suggesting that these cells undergo subculture-induced dediffer-
entiation. Human costal chondrocytes (C28/I2) also show
a decrease in type II collagen expression after serial passage in
monolayer although morphological changes were not observed in
these cells (data not shown). Importantly, our results showing that
endoglin protein levels are higher in late passage as compared to
early passage chondrocytes suggest that endoglin expression is
increased following subculture-induced dedifferentiation. The
increased endoglin protein expression in late passage chondrocytes
is mirrored by an increase in endoglin mRNA expression indicating
that the mechanism of its up-regulation involves an increase in
endoglin gene expression and/or an increase in endoglin mRNA
stability. Our results are consistent with a previous report identi-
fying endoglin as one of many cell surface molecules upregulated in
primary articular chondrocytes during cell expansion in mono-
layer44. Thus, our results suggest that endoglin may represent
a novel marker for chondrocyte dedifferentiation and/or the loss of
normal ‘differentiated’ chondrocyte phenotype.
Factors that regulate TGF-b signalling in normal and ‘pheno-
typically altered’ chondrocytes are ill-deﬁned. A previous study has
shown that ALK1 mRNA levels are increased during in vitro
expansion of primary human articular chondrocytes45 and a more
recent study has reported an increase in the ALK1/ALK5 ratio as
a cause for elevated MMP-13 expression in OA in humans and
mice46. Our results showing that endoglin levels are increased in
human chondrocytes following subculture-induced dedifferentia-
tion in vitro and in human OA cartilage as compared to normal
cartilage in vivo extend these ﬁndings and raise the possibility that
increased expression of endoglin and ALK1 together leads to a shift
in TGF-b signalling away from the ALK5/Smad2/3 pathway in favour
of ALK1/Smad1/5 pathway. Further studies using increased
numbers of age-, sex- and gender-matched OA and normal human
cartilage samples will be needed to conﬁrm these ﬁndings.
K.W. Finnson et al. / Osteoarthritis and Cartilage 18 (2010) 1518e15271526In conclusion, our results establish endoglin as a regulator of
TGF-b signalling and ECM protein productionwith opposing effects
on the ALK1/Smad1/5 and ALK5/Smad2/3 pathways in human
chondrocytes and suggest that endoglin may represent a potential
marker for chondrocyte dedifferentiation or loss of chondrogenic
phenotype. Delineation of the precise mechanism by which endo-
glin may regulate the balance of ALK1 and ALK5 signalling in
human chondrocytes will be a fruitful avenue for future studies.Role of the funding source
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